Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
HCC38 | Etoposide | Topo II | Chemotherapy | 0.33384 | -0.4242 | 0.4494 | 0.1891 | 1.4384 | 0.50554 | 0.99763 |
HCC38 | Topotecan | Topo I | Chemotherapy | 0.0068073 | -0.5041 | 1.0724 | 0.3904 | 1.2181 | 0.011735 | 0.99338 |
HCC38 | Taxol | Chemo | Chemotherapy | 0.0014659 | -0.3078 | 0.8432 | 0.2758 | 2.3201 | 0.0017274 | 0.99328 |
HCC38 | Doxorubicin | Chemo | Chemotherapy | 0.0095452 | -0.4061 | 0.7803 | 0.2872 | 1.4810 | 0.01343 | 0.99228 |
HCC38 | Cisplatin | Chemo | Chemotherapy | 0.99272 | -0.1031 | 0.2567 | 0.1098 | 1.4350 | 1.1794 | 0.99675 |
HCC38 | Dinaciclib | pan CDK | Cell cycle | 0.012678 | -0.4422 | 0.6326 | 0.2241 | 4.1199 | 0.014763 | 0.99821 |
HCC38 | Volasertib | PLK | Cell cycle | 0.0081934 | -0.2598 | 0.6001 | 0.1943 | 3.2088 | 0.0091367 | 0.99678 |
HCC38 | AZD7762 | CHK1/2 | Cell cycle | 0.0094764 | -0.3341 | 0.9185 | 0.2951 | 2.0434 | 0.01177 | 0.98869 |
HCC38 | Palbociclib | CDK4/6 | Cell cycle | 0.059804 | 0.1474 | 0.3722 | 0.0411 | 1.0985 | 0.037879 | 0.98636 |
HCC38 | Abemaciclib | CDK4/6 | Cell cycle | 0.044561 | -0.3272 | 0.6404 | 0.0910 | 0.4303 | 0.21535 | 0.96385 |
HCC70 | Cabozantinib | VEGFR2/MET | RTK | 1.5024 | -0.0911 | 0.2658 | 0.0226 | 0.5892 | 9.6961 | 0.92355 |
HCC70 | Cediranib | VEGFR/cKIT | RTK | 4.5386 | -0.3262 | 0.0890 | 0.0440 | 2.2440 | 7.4053 | 0.99062 |
HCC70 | Tivantinib | MET | RTK | 0.3335 | -0.5657 | 0.4968 | 0.1515 | 2.0000 | 0.48673 | 0.99617 |
HCC70 | Neratinib | EGFR/HER2 | RTK | 0.16013 | 0.0595 | 0.3178 | 0.0405 | 1.0555 | 0.15156 | 0.99467 |
HCC70 | Ceritinib | ALK | RTK | 3.1923 | -0.8808 | 0.1379 | 0.0703 | 5.0000 | 3.9213 | 0.99483 |
HCC70 | Pictilisib | pan PI3K | PI3K/mTOR | 0.16052 | -0.5972 | 0.5726 | 0.1167 | 0.7256 | 0.58082 | 0.99601 |
HCC70 | Buparlisib | pan PI3K | PI3K/mTOR | 0.43342 | -0.7274 | 0.4614 | 0.1434 | 1.1927 | 1.0047 | 0.99537 |
HCC70 | PF-4708671 | p70S6K | PI3K/mTOR | Inf | 0.9348 | -0.0227 | 0.0035 | 0.0000 | Inf | 0.040075 |
HCC70 | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0048011 | -0.1620 | 0.7024 | 0.0912 | 1.1840 | 0.0050026 | 0.97794 |
HCC70 | Everolimus | mTOR1 | PI3K/mTOR | 0.24351 | 0.3727 | 0.4764 | 0.0448 | 0.1135 | 51.0339 | 0.79604 |
HCC70 | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0058452 | -0.5550 | 0.6451 | 0.1234 | 0.5307 | 0.026938 | 0.94991 |
HCC70 | TGX221 | PI3Kb | PI3K/mTOR | 0.092754 | 0.0049 | 0.4729 | 0.0591 | 0.8818 | 0.076452 | 0.9787 |
HCC70 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.15092 | -0.6846 | 0.5796 | 0.1546 | 0.7043 | 0.64661 | 0.98584 |
HCC70 | Alpelisib | PI3Ka | PI3K/mTOR | 4.4987 | 0.0981 | 0.1182 | 0.0196 | 1.0448 | 12.8744 | 0.95143 |
HCC70 | Ipatasertib | AKT | PI3K/mTOR | 0.1397 | -0.2624 | 0.4974 | 0.0860 | 0.8534 | 0.21677 | 0.98567 |